Abstract:Importance Neoadjuvant therapy combining programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors with platinum-based chemotherapy has demonstrated significant improvement in pathologic response and survival rates among patients with resectable non-small cell lung cancer (NSCLC). However, it remains controversial whether PD-1 blockade therapy given before and after surgery (neoadjuvant-adjuvant treatment) is associated with better outcomes than when given only before surgery (neoadjuvant-only treatment). Objective To compare the efficacy and safety associated with neoadjuvant-adjuvant anti-PD-1 and anti-PD-L1 therapy with neoadjuvant-only anti-PD-1 and anti-PD-L1 therapy for patients with resectable NSCLC. Data SourcesA systematic search was conducted across databases including PubMed, Embase, and the Cochrane Library, as well as major oncology conferences, through July 31, 2023. Study Selection Randomized clinical trials comparing neoadjuvant-adjuvant or neoadjuvant-only PD-1 and PD-L1 inhibitor therapy vs chemotherapy alone for patients with resectable NSCLC were selected. Data Extraction and Synthesis Following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline, 2 authors independently extracted data. Hazard ratios (HRs) and 95% CIs for event-free survival (EFS) and overall survival (OS) were extracted and then pooled through the generic inverse-variance methods. Relative risks (RRs) for treatment-related adverse events (TRAEs) were derived via the Mantel-Haenszel method. Using chemotherapy as a common comparator, indirect comparisons between neoadjuvant-adjuvant immunotherapy and neoadjuvant-only immunotherapy were conducted using frequentist methods. A random or fixed model was used based on intertrial heterogeneity identified through the Cochran Q test. Main Outcomes and MeasuresThe primary outcome was EFS, with secondary outcomes including OS and TRAEs. Results The study encompassed 4 trials of neoadjuvant-adjuvant immunotherapy and 1 trial of neoadjuvant-only immunotherapy, involving 2385 patients. Direct meta-analysis revealed significant improvements in EFS for both neoadjuvant-adjuvant and neoadjuvant-only immunotherapy compared with chemotherapy alone. In indirect meta-analysis, the addition of adjuvant immunotherapy to neoadjuvant immunotherapy was not associated with improved EFS (HR, 0.90; 95% CI, 0.63-1.30; P = .59) or OS (HR, 1.18; 95% CI, 0.73-1.90; P = .51) compared with neoadjuvant-only immunotherapy. Moreover, the incidence of any grade of TRAEs significantly increased with the addition of adjuvant immunotherapy (RR, 1.08; 95% CI, 1.00-1.17; P = .04). Conclusions and Relevance This meta-analysis suggests that adding PD-1 or PD-L1 inhibitors in the adjuvant phase to neoadjuvant treatment with PD-1 or PD-L1 inhibitors and chemotherapy may not improve survival outcomes for patients with resectable NSCLC and may be associated with increased adverse events. Future validation of these findings is warranted through head-to-head randomized clinical trials.

The Optimal Neoadjuvant Regimen for Nonsmall Cell Lung Cancer: A Meta-Analysis

Short-term Outcome of Neoadjuvant Immunotherapy and Chemotherapy in Non–small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Efficacy of Neoadjuvant Immunochemotherapy and Survival Surrogate Analysis of Neoadjuvant Treatment in IB–IIIB Lung Squamous Cell Carcinoma

Efficacy, safety, and survival of neoadjuvant immunochemotherapy in operable non-small cell lung cancer: a systematic review and meta-analysis

Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials

Neoadjuvant Immunotherapy or Chemoimmunotherapy in Non-Small Cell Lung Cancer: a Systematic Review and Meta-Analysis

Efficacy and Safety of Neoadjuvant Immunotherapy Plus Chemotherapy in Operable NSCLC: A Meta-Analysis

Treatment Patterns and Clinical Outcomes of Patients with Resectable Non–small Cell Lung Cancer Receiving Neoadjuvant Immunochemotherapy: A Large-Scale, Multicenter, Real-World Study (Neor-World)

Effectiveness and Safety of Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer: A Meta-Analysis

Efficacy and safety of perioperative, neoadjuvant, or adjuvant immunotherapy alone or in combination with chemotherapy in early-stage non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials

Clinical Efficacies of Different Neoadjuvant Therapies for Non-Small Cell Lung Cancer

Comparisons of Perioperative Outcomes after Neoadjuvant Therapies in Patients with Resectable Non-Small Cell Lung Cancer

Neoadjuvant Chemoimmunotherapy for NSCLC

The Efficacy and Safety of Neoadjuvant Immunotherapy in Patients with Non-Small Cell Lung Cancer

Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients’ overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study

Bayesian Network Meta-Analysis of Efficacy and Safety of Neoadjuvant Therapy for Non-Small-cell Lung Cancer

Efficacy and safety of neoadjuvant immunotherapy protocols and cycles for non-small cell lung cancer: a systematic review and meta-analysis

Neoadjuvant-Adjuvant Vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients with Resectable NSCLC

Efficacy and safety of different cycles of neoadjuvant immunotherapy in resectable non-small cell lung cancer: A systematic review and meta-analysis

Investigation of the Optimal Platinum-Based Regimen in the Postoperative Adjuvant Chemotherapy Setting for Early-Stage Resected Non-Small Lung Cancer: a Bayesian Network Meta-Analysis

A Meta‐Analysis of Efficacy and Safety of Neoadjuvant Immunotherapy Plus Chemotherapy for Resectable Non‐Small Cell Lung Cancer